Revvity Inc. (NYSE:RVTY) saw its stock rise by 3.17% as it reached a 20-day high, reflecting positive investor sentiment ahead of its upcoming earnings report.
The company anticipates a Q4 2025 revenue of approximately $772 million, which exceeds market expectations of $760.6 million, indicating strong performance and resilience in a competitive market. Additionally, Revvity expects its full-year adjusted earnings per share to surpass the upper end of its previous guidance of $4.90 to $5.00, showcasing management's confidence in future profitability. This positive outlook has likely contributed to the stock's upward movement.
As Revvity prepares to release its financial results on February 2, 2026, the anticipated revenue growth and strong earnings outlook may attract further investor interest, solidifying its position in the market.
Wall Street analysts forecast RVTY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RVTY is 113.38 USD with a low forecast of 105.00 USD and a high forecast of 123.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
Wall Street analysts forecast RVTY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RVTY is 113.38 USD with a low forecast of 105.00 USD and a high forecast of 123.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
4 Hold
0 Sell
Moderate Buy
Current: 111.130
Low
105.00
Averages
113.38
High
123.00
Current: 111.130
Low
105.00
Averages
113.38
High
123.00
Evercore ISI
Outperform
maintain
$108 -> $112
2026-01-05
Reason
Evercore ISI
Price Target
$108 -> $112
AI Analysis
2026-01-05
maintain
Outperform
Reason
Evercore ISI raised the firm's price target on Revvity to $112 from $108 and keeps an Outperform rating on the shares. Recovering end markets and sector rotation have "set the stage for a 2026 Tools play," the analyst tells investors. In MedTech, the firm's survey work points to healthy procedure and CapEx trends into 2026 and early recovery signs in China support the group, but sector rotation and potential ACA and Medicare changes "have bears watching," the analyst added.
Barclays
Luke Sergott
Overweight
maintain
$105 -> $115
2025-12-15
Reason
Barclays
Luke Sergott
Price Target
$105 -> $115
2025-12-15
maintain
Overweight
Reason
Barclays analyst Luke Sergott raised the firm's price target on Revvity to $115 from $105 and keeps an Overweight rating on the shares. The firm adjusted ratings and price targets in the life sciences and diagnostics tools space as part of its 2026 outlook. The last of the estimate cuts, recovering end markets and tools being the "most under-owned space in healthcare" creates a "great setup" for outperformance of the tools group in 2026, the analyst tells investors in a research note.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for RVTY
Unlock Now
BofA
Buy
to
Neutral
downgrade
$105 -> $110
2025-12-15
Reason
BofA
Price Target
$105 -> $110
2025-12-15
downgrade
Buy
to
Neutral
Reason
BofA downgraded Revvity to Neutral from Buy with a price target of $110, up from $105.
Wells Fargo
Brandon Couillard
Equal Weight
maintain
$102 -> $107
2025-12-15
Reason
Wells Fargo
Brandon Couillard
Price Target
$102 -> $107
2025-12-15
maintain
Equal Weight
Reason
Wells Fargo analyst Brandon Couillard raised the firm's price target on Revvity to $107 from $102 and keeps an Equal Weight rating on the shares. With U.S. policy uncertainty lifting on Pharma and forward growth expectations already well-anchored with room for upside, the firm likes the setup for Tools.
About RVTY
Revvity, Inc. is a provider of health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. The Company has specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. Its segments include Life Sciences and Diagnostics. The Life Sciences segment provides products and services targeted towards the life sciences market. The segment offers instruments, reagents, software, detection and imaging technologies, and others. The Diagnostics segment develops diagnostics, tools, and applications focused on clinically oriented customers, within the reproductive health, immunodiagnostics, and applied genomics markets. The segment offers instruments, reagents, assay platforms and software to hospitals, medical labs, clinicians and medical research professionals to help improve the health of families.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
